JanOne develops therapies intended to treat diseases that cause severe pain and to reduce dependence on opioid-based treatments. The company focuses on non-addictive pharmacologic approaches that address pain by targeting underlying vascular and neuropathic conditions. Its lead product candidate, JAN101, is designed for patients with peripheral